LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab

A Phase I, Open-label, Multi-arm, Multi-centre, Multi-dose, Dose Escalation Study of LTX-315 as Monotherapy or in Combination With Either Ipilimumab or Pembrolizumab in Patients With Transdermally Accessible Tumours

The study will assess the safety, tolerability, PK and efficacy of different intra-tumoral dosing regimens of LTX-315; a lytic-peptide that induces long-term anti-cancer immune responses, as monotherapy or in combination with ipilimumab or pembrolizumab.

Study Overview

• Status: Completed
• Conditions: Melanoma; Lymphoma; Cancer; Breast Cancer; Head and Neck Cancer; Triple-Negative Breast Cancer
• Intervention / Treatment: Drug: LTX-315 consecutive lesions; Drug: LTX-315; Drug: LTX-315 + ipilimumab; Drug: LTX-315 + pembrolizumab

Detailed Description

In this phase I, open-label, multi-arm, multicentre, multi-dose dose escalation study in patients with transdermally accessible tumours; the safety, PK and efficacy of different dosing regimens of LTX-315 will be assessed.

Patients will be allocated into 4 separate (parallel) arms depending on the tumour type and the number of lesions available.

Arm A: Single lesion/sequential lesion treatment arm (LTX-315 monotherapy) (Completed) Arm B: Concurrent multiple lesion treatment arm with all tumour types (LTX-315 monotherapy) Arm C: LTX-315 combination with ipilimumab in patients with melanoma Arm D: LTX-315 combination with pembrolizumab in patients with TNBC

All patients will have at least one lesion available for injection.

Treatment schedule:

Arm A: Injection of LTX-315 3 days week 1, 1 day in week 2, 3, 4, 5 and 6. Every 2 weeks starting with week 8.

Arm B (all tumours): Injection of LTX-315 2 days week 3 weeks (Day 1, 2, 8, 9, 15 and 16).

Arm C (melanoma): Injection of lTX-315 2 days week 3 weeks (Day 1, 2, 8, 9, 15 and 16) in combination with ipilimumab given in week 1 and every 3 weeks 4 cycles.

Arm D (TNBC): Injection of LTX-315 2 days week 3 weeks (Day 1, 2, 8, 9, 15 and 16) in combination with pembrolizumab given in week 1 and every 3 weeks up to 2 years.

Patients will be enrolled into a dose cohort in order of study entry. Staring with the lowest dose. A minimum of 3 patients will be enrolled into each cohort. Dose escalation determined by the Safety Review Committee and the Sponsor. The the optimal regimen will be based on the results of the Dose Escalation from the following information:

1. Safety parameters including blood samples and cardiovascular effects
2. Immunohistology and ultrasound confirmation of necrosis and tumour infiltrating lymphocytes
3. Systemic inflammatory response
4. Evidence of clinical responses

Cohorts may be utilized to:

1. Evaluate different doses of LTX-315
2. Explore potential modifications to the dosing schedule
3. Evaluate the potential to include appropriate combination therapies with LTX-315
4. Gain further information on clinical efficacy

• Study Type: Interventional
• Enrollment (Anticipated): 80
• Phase: Phase 1

Contacts and Locations

Study Locations

• Belgium
  • Bruxelles, Belgium, 1000
    • Jules Bordet Institute
  • Bruxelles, Belgium, 1200
    • Cliniques Universitaires St-Luc, Service d'oncologie médicale
• France
  • Paris, France, 75248
    • Institut Curie
  • Paris, France, 94805
    • Institute Gustave Roussy
• Italy
  • Milano, Italy, 20141
    • Intotuto Europeo di Oncologia (IEO)
  • Milano, Italy, 20141
    • San Raffaele Hospital
  • Napoli, Italy, 80131
    • Intituto Nazionale dei Tumori
  • Padova, Italy, 35128
    • Instituto Oncologico Venneto (IOV)
• Norway
  • Bergen, Norway, 5021
    • Haukeland University Hospital
  • Oslo, Norway, 0379
    • Oslo university hospital Radiumhospitalet
• United Kingdom
  • London, United Kingdom, SE1 9RT
    • Guy's Hospital
  • London, United Kingdom, SW3 6JJ
    • Royal Marsden Hospital
  • London, United Kingdom, WC 1E
    • University College of London Hospital
  • Manchester, United Kingdom, M20 4BX
    • Christie Hospital NHS Foundatin Trust

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

Arm A: (Recruitment completed)

Arm B:

• Unresectable metastatic disease (any tumor type) and conventional anti-tumor treatment is not appropriate.
• Have at least one available lesion (cutaneous, sub-cutaneous, oral or lymph node) for injection between 1-3 cm longest diameter and one bystander lesion (non-injected).

Arm C:

• Have unresectable/metastatic diagnosis of malignant melanoma (histologically confirmed).
• Have at least one available lesion (cutaneous, sub-cutaneous, oral or lymph node) for injection and biopsy which is between 1 and 3 cm in longest diameter.
• Have had previous treatment with an anti-PD-1 antibody (as monotherapy or as part of combination (any combination) as 1st or 2nd line metastatic treatment).

Arm D:

• Have unresectable/metastatic diagnosis of triple negative breast cancer (histologically confirmed).
• Have at least one available lesion (cutaneous, sub-cutaneous or lymph node) for injection and biopsy with a minimum longest diameter of 1 cm.
• Have received between one and 4 prior systemic treatments for metastatic triple negative breast cancer.

All arms:

• Be willing to undergo repeat tumour biopsy and/or tumour resection procedures.
• Have an ECOG Performance status (PS): 0 - 1.

• Meet the following laboratory requirements:

  1. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
  2. Absolute lymphocyte count ≥ 0.8 x 109/L
  3. Platelet count ≥ 75 x 109/L
  4. Haemoglobin ≥ 9.0 g/dL
  5. aPTT/PT within the institution's normal range
  6. Total bilirubin level ≤ 1.5 x ULN
  7. ASAT and ALAT ≤ 2.5 x ULN (≤5 x ULN if liver metastasis present)
  8. Creatinine ≤ 1.5 x ULN

  9. Albumin ≥ 30 g/L

     Exclusion Criteria:

     Arm A: (Completed)

     Arm B:

• Have a history of systemic auto-immune disease requiring anti-inflammatory or immunosuppressive therapy within the last 3 months. Patients with history of autoimmune thyroiditis are eligible provided the patient requires only thyroid hormone replacement therapy and disease has been stable for ≥ 1 year.

Arm C:

• Have had prior therapy with ipilimumab or any other anti-CTLA-4 monoclonal antibody.
• Have had BRAF/MEK inhibitors administered within 2 weeks prior to the study drug administration.
• Have active systemic autoimmune disease; have had prior pneumonitis; have a history of severe hypersensitivity to another monoclonal antibody; are receiving immunosuppressive therapy; have a history of severe immune-related adverse reaction from treatment with a monoclonal antibody, defined as any Grade 4 or 3 toxicity requiring corticosteroid treatment (> 10 mg/day prednisone or equivalent) for greater than 12 weeks.

Arm D:

• Have had prior therapy with an anti-PD-1 or anti-PD-L1 monoclonal antibody.
• Have received cancer immunotherapy within 2 weeks prior to study drug administration or have not recovered from adverse events (to ≤ CTCAE grade 1) due to such agents.
• Have active systemic autoimmune disease; have had prior pneumonitis; have a history of severe hypersensitivity to another monoclonal antibody; are receiving immunosuppressive therapy; and have a history of severe immune-related adverse reactions from treatment with a monoclonal antibody, defined as any Grade 4 or 3 toxicity requiring corticosteroid treatment (> 10 mg/day prednisone or equivalent) for greater than 12 weeks.

All arms:

• Have received external radiotherapy or cytotoxic chemotherapy within 4 weeks prior to study drug administration, or have not recovered from adverse events (≤ CTCAE grade 1) due to agents administered more than 4 weeks earlier. Palliative radiotherapy to non-target lesions within 4 weeks prior to study drug administration is allowed.
• Are currently taking any agent with a known effect on the immune system. Patients are allowed to be on a stable dose of corticosteroids (up to 10 mg daily prednisolone or equivalent) for at least 2 weeks prior to study drug administration (please see Appendix IV for prohibited medications).

• Have any other serious illness or medical condition such as, but not limited to:

  1. Uncontrolled infection or infection requiring antibiotics
  2. Uncontrolled cardiac failure: Classification III or IV (New York Heart Association)
  3. Uncontrolled systemic and gastro-intestinal inflammatory conditions
  4. Bone marrow dysplasia
• Have a known history of positive tests for HIV/AIDS, or have active hepatitis B or C (based on serology).

• Are expected to need any other anti-cancer therapy or immunotherapy to be initiated during the study period.

  15. Have clinically active or unstable CNS metastases as assessed by the treating physician.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm A: LTX-315 monotherapy singe lesion; Cohort 1-3: First induction treatment (6 weeks): In week 1 the first index lesion will be injected Twice daily on 3 consecutive days. During week 2-6 the injection will be once a week. Second induction treatment (6 weeks) and Maintenance treatment (20 weeks)- At week 7 the second index lesion will be injected with same dosing schedule as the first index lesion. Cohort 4 and above: Once daily on 3 consecutive days week 1. Week 2-6 one injection per week. From week 8, one dosing days every 2 weeks.	Drug: LTX-315 consecutive lesions; Dose escalation: Cohort 1: 2 mg twice per day (4 mg) Cohort 2: 3 mg twice per day (6 mg) Cohort 3: 4 mg twice per day (8 mg); Other Names: Protocol version 4
Experimental: Arm B: LTX-315 monotherapy in multiple concurrent lesions; Patients with at least one injectable lesion and one bystander lesion will receive LTX-315 to one or more lesions: Once daily on 2 consecutive days week 1-3.	Drug: LTX-315; Dose escalation: Cohort 1: 3 mg per injection Cohort 2: 4 mg per injection Cohort 3: 5 mg per injection; Other Names: Arm B (Protocol version 6)
Experimental: Arm C; Patients with melanoma and at least one injectable lesion will receive LTX-315 to one or more lesions on two consecutive days week 1-3 in combination with ipilimumab given for 4 cycles every 3 weeks.	Drug: LTX-315 + ipilimumab; Cohort 1: 3 mg per injection + 3 mg/kg ipilumumab Cohort 2: 4 mg per injection + 3 mg/kg ipilumumab Cohort 3: 5 mg per injection + 3 mg/kg ipilumumab; Other Names: Arm C (Protocol version 6)
Experimental: Arm D; Patients with TNBC and at least one injectable lesion will receive LTX-315 to one or more lesions on two consecutive days week 1-3 in combination with pembrolizumab given every 3 weeks.	Drug: LTX-315 + pembrolizumab; Cohort 1: 3 mg per injection + 200 mg pembrolizumab Cohort 2: 4 mg per injection + 200 mg pembrolizumab Cohort 3: 5 mg per injection + 200 mg pembrolizumab; Other Names: Arm D (Protocol version 6)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Dose limiting toxicity	Dose limiting toxicities (DLT) and the overall safety profile (adverse events (AE), laboratory assessments, physical findings and symptomatic assessment) of LTX-315 as monotherapy and in combination with ipilimumab or pembrolizumab.	21 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Anti tumour activity in injected tumour	Number of patients with regression of injected tumour assessed by ultrasound and/or CT/MRI.	Every 8 weeks from treatment start up to 24 months or first documented progression documented assessed
Complete response (irCR) and partial response (irPR)	Number of patients by irRC	Every 8 weeks from treatment start up to 24 months or first documented progression documented assessed
Overall response rate (OR)	(irRC criteria)	Every 8 weeks from treatment start up to 24 months or first documented progression documented assessed
Disease control rate (CR + PR + SD)	irRC criteria	Every 8 weeks from treatment start up to 24 months or first documented progression documented assessed
Progression free survival (PFS)	irRC criteria	Every 8 weeks from treatment start up to 24 months or first documented progression documented assessed

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetic (PK) profile of LTX-315	Measurement of plasma concentrations of LTX-315 pre- and 1 hour post-dosing day 2 in week 1.	Pre and 1 hour post dosing Day 2 Week 1

Collaborators and Investigators

• Sponsor: Lytix Biopharma AS
• Collaborators: ICON plc; Theradex
• Investigators: Principal Investigator: James Spicer, MD, PhD, Guy's Hospital

Publications and helpful links

General Publications

• Spicer J, Marabelle A, Baurain JF, Jebsen NL, Jossang DE, Awada A, Kristeleit R, Loirat D, Lazaridis G, Jungels C, Brunsvig P, Nicolaisen B, Saunders A, Patel H, Galon J, Hermitte F, Camilio KA, Mauseth B, Sundvold V, Sveinbjornsson B, Rekdal O. Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors. Clin Cancer Res. 2021 May 15;27(10):2755-2763. doi: 10.1158/1078-0432.CCR-20-3435. Epub 2021 Feb 4.
• Jebsen NL, Apelseth TO, Haugland HK, Rekdal O, Patel H, Gjertsen BT, Jossang DE. Enhanced T-lymphocyte infiltration in a desmoid tumor of the thoracic wall in a young woman treated with intratumoral injections of the oncolytic peptide LTX-315: a case report. J Med Case Rep. 2019 Jun 10;13(1):177. doi: 10.1186/s13256-019-2088-6.

Study record dates

Study Major Dates

• Study Start (Actual): November 1, 2013
• Primary Completion (Actual): April 1, 2018
• Study Completion (Actual): August 31, 2018

Study Registration Dates

• First Submitted: October 28, 2013
• First Submitted That Met QC Criteria: November 11, 2013
• First Posted (Estimate): November 18, 2013

Study Record Updates

• Last Update Posted (Actual): October 3, 2018
• Last Update Submitted That Met QC Criteria: October 2, 2018
• Last Verified: May 1, 2018

More Information

Terms related to this study

• Keywords: Transdermal accessible tumours
• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms; Triple Negative Breast Neoplasms; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Antineoplastic Agents, Immunological; Immune Checkpoint Inhibitors; Pembrolizumab; Ipilimumab
• Other Study ID Numbers: C12-315-03

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No